第五次年度儿科机械循环支持机构间注册(Pedimacs)报告
Pedimacs注册报告了2012年9月19日至2020年12月31日期间来自47家北美医院的1011例年龄小于19岁的儿科心室辅助装置(VAD)患者共1229台装置。心肌病是最常见病因(58%),其次为先天性心脏病(25%)和心肌炎(10%)。植入装置以植入式连续流(IC)最常见(41%),总体6个月阳性结局(移植、撤除或带装置存活)为83%。
要点
- 心肌病是儿科VAD支持最常见病因(58%),其次为先天性心脏病(25%)和心肌炎(10%)。
- 植入式连续流VAD最常见(41%),其次为体外搏动式(27%)、体外连续流(26%)和经皮式(5%)。
- 6个月总体阳性结局为83%,3个月无卒中率IC VAD最高(93%),PP为84%,PC为75%。
核心结论
- Pedimacs第五次报告显示儿科VAD应用持续增长,注册患者已超过1000例。
- 不同装置类型(PC、PP、IC)服务于VAD植入前风险特征不同的患者群体,这可能解释装置类型间生存率和不良事件的差异。
研究设计与样本
- Pedimacs注册是一项多中心儿科机械循环支持注册研究。
- 2012年9月19日至2020年12月31日期间,47家北美医院报告了1011例年龄小于19岁患者的1229台装置。
主要发现
- 心肌病是最常见的基础病因(58%),其次为先天性心脏病(25%)和心肌炎(10%)。
- 植入装置类型:植入式连续流419台(41%),体外搏动式269台(27%),体外连续流263台(26%),经皮式53台(5%)。
- VAD植入后6个月,83%的患者获得阳性结局(移植、撤除或带装置存活)。
- 3个月无卒中率:植入式连续流VAD为93%,体外搏动式VAD为84%,体外连续流VAD为75%。
- 不同装置类型的生存率存在差异,植入式连续流VAD患者总生存率最佳,体外连续流VAD最低,但各装置类型支持的患者群体存在显著差异。
临床怎么用
- 儿科VAD选择需考虑装置类型对应的患者风险特征差异,植入式连续流VAD与较高的3个月无卒中率和总生存率相关。
- 注册数据可用于咨询和机构间比较,但装置类型间的生存差异可能受患者选择偏倚影响。
局限性
- 各VAD装置类型支持的患者群体风险特征显著不同,可能混淆装置类型间生存率和不良事件的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) provides detailed information on pediatric patients supported with ventricular assist devices (VADs). METHODS: From September 19, 2012, to December 31, 2020, 1229 devices in 1011 patients were reported to the registry from 47 North American Hospitals in patients aged younger than 19 years. RESULTS: Cardiomyopathy was the most common underlying etiology (58%), followed by congenital heart disease (CHD; 25%) and myocarditis (10%). The most common devices implanted were implantable continuous (IC; 419 [41%]), followed by paracorporeal pulsatile (PP; 269 [27%]), paracorporeal continuous (PC; 263 [26%]), and percutaneous (53 [5%]). Overall, at 6 months after VAD implantation, 83% had a positive outcome (transplant, explant, or alive on device). The freedom from stroke at 3 months was highest in IC VADs (93%), compared with PP VADs (84%) and with PC VADs (75%). There were differences in survival by device type, with patients on IC VADs having the best overall survival and those on PC having the lowest overall survival, though the patient populations being supported by each VAD type differed significantly from each other. CONCLUSIONS: This Fifth Pedimacs Report demonstrates the continued robust growth of VADs in the pediatric community, now with more than 1000 patients reported to the registry. The multiple available device types (PC, PP, IC) serve different populations with different pre-VAD risk profiles, which may account for differences in survival and adverse events between device types.
引用
- Rossano JW, VanderPluym CJ, Peng DM, et al. Fifth Annual Pediatric Interagency Registry for Mechanical Circulatory Support (Pedimacs) Report. Ann Thorac Surg. 2021. PMID: 34648810. doi:10.1016/j.athoracsur.2021.10.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。